Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation | MicrobiomeTrials← Back to trialsNCT07405671
Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-09Est. Completion: 2029-12
Enrollment target: 988 participants Locations- AZorg, Aalst, Belgium
- Imelda, Bonheiden, Belgium
- AZ ST-JAN Brugge A.V., Bruges, Belgium
- Universitair Ziekenhuis Antwerpen, Edegem, Belgium
- Ziekenhuis Oost Limburg, Genk, Belgium
- Az Maria Middelares Gent, Ghent, Belgium
- AZ St.-Elisabeth Herentals VZW, Herentals, Belgium
- Jan Yperman Ziekenhuis, Ieper, Belgium
- Algemeen Ziekenhuis Groeninge, Kortrijk, Belgium
- UZ Leuven, Leuven, Belgium
- Algemeen Ziekenhuis Delta, Roeselare, Belgium
- AZ Rivierenland, Rumst, Belgium
- Vitaz, Sint-Niklaas, Belgium
- AZ Turnhout, Turnhout, Belgium
Other microbiome trials you might be interested in
Persistent Atrial Fibrillation
The goal of this clinical study is to find out which treatment works best for people with persistent atrial fibrillation…
Bruges, BelgiumEst. completion Jan 2027
Atrial Fibrillation (AF)Pulmonary Embolism (PE)Left Atrial Appendage Thrombosis
This study aims to investigate whether a quick, additional CT scan of the heart, performed immediately after a standard …
Manhasset, United StatesEst. completion Apr 2027
Recruiting
StrokeImplantation of an Implantable Cardiac Monitor
Atrial fibrillation is a cardiac arrhythmia most often originating in the left atrium, causing anarchic electrical activ…
Dijon, FranceEst. completion Jan 2031